Literature DB >> 1349642

Use of 2-hydroxypropyl-beta-cyclodextrin as an intrathecal drug vehicle with opioids.

J Jang1, T L Yaksh, H F Hill.   

Abstract

2-Hydroxypropyl-beta-cyclodextrin (CDEX), a seven-membered glucose pyranose structure, forms reversible inclusion complexes with the lipophilic portion of a drug molecule by noncovalent bonding. This can increase the water solubility of lipid-soluble drugs and reduce the rate of clearance of such agents from the spinal cord into the vasculature after i.t. administration. In this study, opioids (morphine, lofentanil, alfentanil and sufentanil) with and without CDEX (20, 2, 0.2 and 0.02% w/v in sterile water) were administered spinally in rats prepared with chronic i.t. catheters. CDEX prolonged the duration of analgesia (52.5 degrees C hot plate) and reduced the incidence of catalepsy otherwise produced by a supermaximal i.t. dose of each of the opioids. The magnitude of the potentiating effect of CDEX on opioids was dependent upon concentration of the CDEX and varied with drug lipid partition coefficients. The highest concentration of CDEX alone (20%) had no effect upon the volume-evoked micturition reflex, blood pressure, heart rate, or spinal reflexes. Our data indicate that CDEX may be a useful i.t. vehicle for modifying the redistribution characteristics of highly diffusible molecules after their i.t. administration, and that for each drug there is an optimal CDEX concentration. In the present case, CDEX prolongs the spinal analgesic action and reduces the supraspinal actions of i.t. drugs.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1349642

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  5 in total

1.  Controlled systemic absorption and increased anesthetic effect of bupivacaine following epidural administration of bupivacaine-hydroxypropyl-beta-cyclodextrin complex.

Authors:  J C Fréville; G Dollo; P Le Corre; F Chevanne; R Le Verge
Journal:  Pharm Res       Date:  1996-10       Impact factor: 4.200

2.  Analgesic properties of loperamide differ following systemic and local administration to rats after spinal nerve injury.

Authors:  C Chung; A F Carteret; A D McKelvy; M Ringkamp; F Yang; T V Hartke; X Dong; S N Raja; Y Guan
Journal:  Eur J Pain       Date:  2012-04-16       Impact factor: 3.931

Review 3.  Current and Future Issues in the Development of Spinal Agents for the Management of Pain.

Authors:  Tony L Yaksh; Casey J Fisher; Tyler M Hockman; Ashley J Wiese
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

4.  Characterization of methyl-beta-cyclodextrin toxicity in NGF-differentiated PC12 cell death.

Authors:  Joel E Ulloth; Frankis G Almaguel; Amelia Padilla; Liming Bu; Jo-Wen Liu; Marino De Leon
Journal:  Neurotoxicology       Date:  2007-01-13       Impact factor: 4.294

5.  An initial animal proof-of-concept study for central administration of clozapine to schizophrenia patients.

Authors:  Daniel J Abrams; Lijun Zheng; Kevin S Choo; Jun J Yang; Wei Wei; Thomas J Anchordoquy; Nasser H Zawia; Karen E Stevens
Journal:  Schizophr Res       Date:  2008-01-07       Impact factor: 4.939

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.